Mason et al reported overall testing rates in advanced non‐squamous NSCLC for EGFR, ALK, and ROS1 from 85% to 100%, with rates of 100% across these mutations in the academic setting. This evidence concerns the gene ALK and non-small cell lung carcinoma.